CAJ | 학술논문

目的：评价低剂量吉西他滨延时输注联合奈达铂治疗转移性鼻咽癌的疗效及耐受性。方法选择26例复发或转移性鼻咽癌患者，治疗第1、8日，予吉西他滨250 mg/m2，持续输注6 h；治疗第1日予奈达铂80 mg/m2，持续输注2 h；每28 d重复1次。观察治疗反应率（ORR）、无进展生存期（PFS）、1年生存率及其毒副作用。结果26例患者的ORR为81％。中位随访时间13（95％CI 10～19）个月，中位PFS为7个月（95％CI 5.0～11）个月，1年生存率为58％。血液学毒性反应耐受良好，Ⅰ～Ⅱ级白细胞、血小板减少的发生率分别为54％和39％，未观察到Ⅲ～Ⅳ级白细胞减少及血小板减少。非血液学毒性轻微，胃肠道反应发生率为23％，口咽黏膜炎发生率为70％，脱发发生率为46％。结论低剂量延时输注吉西他滨联合奈达铂治疗转移性鼻咽癌疗效可，毒副作用相对较轻。
목적：평개저제량길서타빈연시수주연합내체박치료전이성비인암적료효급내수성。방법선택26례복발혹전이성비인암환자，치료제1、8일，여길서타빈250 mg/m2，지속수주6 h；치료제1일여내체박80 mg/m2，지속수주2 h；매28 d중복1차。관찰치료반응솔（ORR）、무진전생존기（PFS）、1년생존솔급기독부작용。결과26례환자적ORR위81％。중위수방시간13（95％CI 10～19）개월，중위PFS위7개월（95％CI 5.0～11）개월，1년생존솔위58％。혈액학독성반응내수량호，Ⅰ～Ⅱ급백세포、혈소판감소적발생솔분별위54％화39％，미관찰도Ⅲ～Ⅳ급백세포감소급혈소판감소。비혈액학독성경미，위장도반응발생솔위23％，구인점막염발생솔위70％，탈발발생솔위46％。결론저제량연시수주길서타빈연합내체박치료전이성비인암료효가，독부작용상대교경。
Objective Toevaluatetheefficacyandtolerabilityofprolongedinfusionoflow-dosegem-citabine combined with nedaplatin in treatment of recurrent/metastatic nasopharyngeal carcinoma. Methods Twenty-sixpatientswithrecurrent/metastaticnasopharyngealcarcinomareceivedgemcitabineatadoseof250 mg/m2 civ for 6h on days 1 and 8;nedaplatin at a dose of 80 mg/m2 was administered on day 1 every 28 days.The overall response rate (ORR),progression-free survival (PFS)and 1-year survival rate and side effects wereevaluated.Results Among26patients,ORRwas80.7%.Themedianfollow-uptimewas13months (95%CI,range:1 0~1 9). The median PFS was 7.0 months (95%CI,range:5-1 0.5). The 1-year survival rate was 57.7%. Hematologic toxicities were well tolerated and the occurrence of grade Ⅰ~Ⅱleukocytopenia and thrombocytopenia were 53.8% and 38.5%. Grade Ⅲ~Ⅳ leukocytopenia and thrombocytopenia were not observed. Mild non-hematologic toxicities were observed with 23.1%of gastrointestinal response,70%of oro-pharyngealmucositisand46%ofalopecia.Conclusion Prolongedinfusionoflow-dosegemcitabineincombi-nation with nedaplatin was efficacious in treatment of metastatic nasopharyngeal carcinoma and yielded relatively mild side effects.